Search results for " Myocardial infarction"

showing 10 items of 247 documents

[Evaluation of resistance to activated protein C in myocardial infarction patients].

2001

It is known that resistance to activated protein C (APCR), often associated with a single point mutation (Arg506--Gln) in the coagulation factor V gene (factor V Leiden), is the most frequent inherited abnormality of blood coagulation. It plays a key role as pathogenetic factor of venous thromboembolism, but its association with an increased risk of arterial thrombosis is uncertain. Aim of the present study was to evaluate the prevalence of APCR in men, who suffered myocardial infarction more than 6 months earlier and without cardiovascular risk factors (hypercholesterolemia, smoking, diabetes, obesity and hypertension).The study was carried on 20 men aged65 years who have suffered myocardi…

MaleMyocardial InfarctionPrevalenceHumansMiddle AgedProtein C resistance myocardial infarctionActivated Protein C ResistanceMinerva cardioangiologica
researchProduct

Behaviour of the neutrophil to lymphocyte ratio in young subjects with acute myocardial infarction

2016

In the last years the neutrophil to lymphocyte ratio (NLR) has been examined in cardiovascular disorders and in particular in coronary artery disease and acute myocardial infarction (AMI). Now we examined this parameter in subjects with juvenile myocardial infarction at the initial stage and after 3 and 12 months. We enrolled 123 young subjects (112 men and 11 women, mean age 39.4 ± 5.8 yrs) with AMI. The time interval between the AMI onset and the investigation was 13 ± 7 days. The mean value of NLR observed in young AMI subjects was significantly increased compared to normal controls (N = 1.817 ± 0.711; young AMI subjects = 2.376 ± 0.873, p <  0.0001). NLR does not discriminate STEMI (2.4…

MaleNeutrophilsPhysiologyLymphocyteMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyCoronary artery diseaseLeukocyte Count0302 clinical medicineRetrospective StudieRisk FactorsMedicineLymphocytes030212 general & internal medicineMyocardial infarctionStage (cooking)HematologyNeutrophilSmokingJuvenile myocardial infarction; leukocyte count; neutrophil/lymphocyte ratio; Adult; Biomarkers; Coronary Angiography; Coronary Artery Disease; Female; Humans; Inflammation; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Myocardial Infarction; Neutrophils; Prognosis; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Smoking; Physiology; Hematology; Cardiology and Cardiovascular Medicine; Physiology (medical)HematologyMiddle AgedPrognosismedicine.anatomical_structureAbsolute neutrophil countCardiologyLymphocyteFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyPrognosi03 medical and health sciencesPhysiology (medical)Internal medicineHumansLymphocyte Countcardiovascular diseasesNeutrophil to lymphocyte ratioRetrospective StudiesInflammationbusiness.industryRisk FactorRetrospective cohort studyBiomarkermedicine.diseaseJuvenile myocardial infarctionneutrophil/lymphocyte ratioST Elevation Myocardial InfarctionbusinessBiomarkersClinical Hemorheology and Microcirculation
researchProduct

Off-pump versus on-pump myocardial revascularization in patients with ST-segment elevation myocardial infarction: A randomized trial

2009

Objective Conventional cardioplegic arrest coronary artery bypass grafting after ST-segment elevation myocardial infarction is associated with high mortality and morbidity. The benefits of off-pump surgery have been suggested. This study randomly evaluated the impact of the off-pump technique on clinical results. Methods Between February 2002 and October 2007, 128 patients with ST-segment elevation myocardial infarction who underwent myocardial revascularization within 48 hours from the onset of symptoms were randomly assigned to 2 groups: on-pump group (66 patients/51.5%) and off-pump group (63 patients/48.5%). The primary end point was the incidence of in-hospital death and outcomes (low …

MalePulmonary and Respiratory MedicineCardiac function curvemedicine.medical_specialtyTime FactorsOff-pump myocardial revascularization on-pump myocardial revascularization ST-segment elevation myocardial infarctionmedicine.medical_treatmentCoronary Artery Bypass Off-PumpMyocardial Infarctionlaw.inventionlawInternal medicineMyocardial RevascularizationCardiopulmonary bypassHumansMedicineMyocardial infarctionAgedbusiness.industryCardiogenic shockST elevationPercutaneous coronary interventionPerioperativeMiddle Agedmedicine.diseaseIntensive care unitCardiologyFemaleSurgeryCardiology and Cardiovascular MedicinebusinessThe Journal of Thoracic and Cardiovascular Surgery
researchProduct

Vorapaxar in the secondary prevention of atherothrombotic events

2012

BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients …

MalePyridines[SDV]Life Sciences [q-bio]Myocardial InfarctionMedizinKaplan-Meier Estimate030204 cardiovascular system & hematologyBrain IschemiaLactones0302 clinical medicineMESH: Peripheral Arterial DiseaseSecondary PreventionMESH: Double-Blind Method030212 general & internal medicineMyocardial infarctionStrokeVorapaxarMESH: AgedAspirinMESH: Middle AgedMESH: RiskCardiovascular diseases [NCEBP 14]MESH: Secondary PreventionHazard ratioMESH: Brain IschemiaGeneral MedicineMiddle AgedClopidogrel3. Good healthStrokeMESH: Receptor PAR-1MESH: Myocardial Infarctionvorapaxar secondary prevention atherothrombotic eventsCardiovascular DiseasesMESH: Platelet Aggregation InhibitorsAnesthesiaRetreatmentPlatelet aggregation inhibitorFemaleIntracranial HemorrhagesMESH: HemorrhageMESH: Intracranial HemorrhagesMESH: Lactonescirculatory and respiratory physiologymedicine.drugRiskISQUEMIA CEREBRALHemorrhagePlaceboMESH: StrokePeripheral Arterial Disease03 medical and health sciencesDouble-Blind Method[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansReceptor PAR-1MESH: RetreatmentMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryMESH: PyridinesMESH: Cardiovascular Diseasesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMESH: MalebusinessMESH: FemalePlatelet Aggregation Inhibitors
researchProduct

Ejection Fraction by Echocardiography for a Selective Use of Magnetic Resonance After Infarction

2020

[EN] Background Cardiac magnetic resonance (CMR) permits robust risk stratification of discharged ST-segment-elevation myocardial infarction patients, but its indiscriminate use in all cases is not feasible. We evaluated the utility of left ventricular ejection fraction (LVEF) by echocardiography for a selective use of CMR after ST-segment-elevation myocardial infarction. Methods Echocardiography and CMR were performed in 1119 patients discharged for ST-segment-elevation myocardial infarction included in a multicenter registry. The prognostic power of CMR beyond echocardiography-LVEF was assessed using adjusted C statistic, net reclassification improvement index, and integrated discriminati…

MaleRiskmedicine.medical_specialtyVentricular Ejection FractionTime FactorsInfarctionMagnetic Resonance Imaging CineHeart failurePatient ReadmissionVentricular Function LeftTECNOLOGIA ELECTRONICAVentricular Dysfunction LeftPercutaneous Coronary InterventionPredictive Value of TestsInternal medicinemedicineHumansVentricular ejection fractionRadiology Nuclear Medicine and imagingcardiovascular diseasesMyocardial infarctionProspective StudiesRegistriesAgedEjection fractionmedicine.diagnostic_testbusiness.industryReproducibility of ResultsMagnetic resonance imagingStroke VolumeMiddle Agedmedicine.diseasePrognosisNet reclassification improvementMyocardial infarctionTreatment OutcomeEchocardiographyMagnetic resonanceHeart failurecardiovascular systemCardiologyST Elevation Myocardial InfarctionFemaleCardiology and Cardiovascular MedicinebusinessMacecirculatory and respiratory physiology
researchProduct

Early detection of coronary artery flow and myocardial perfusion impairment in hypertensive patients evidenced by myocardial blush grade (MBG) and th…

2012

OBJECTIVE: In hypertensive patients with typical chest pain but absence of coronary stenosis the coronary microcirculation may be impaired, thus, our study aimed to appraise, in these subjects, the role of the coronary microcirculation, assessed by Myocardial Blush Grade (MBG) and Thrombolysis in Myocardial Infarction (TIMI) Frame Count (TFC). METHODS: A total of 95 subjects with chest pain and uninjured coronary arteries were recruited into the study: 80 subjects were hypertensive while 15 subjects were normotensive. The hypertensive subjects were divided into two subgroups: hypertensive subjects with positive scintigraphy and hypertensive subjects with negative scintigraphy. The TFC, a qu…

MaleTechnetium Tc 99m SestamibiChest Painmedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionMyocardial IschemiaCoronary AngiographyChest painScintigraphyAnginaElectrocardiographyHypertensive patients MBG TIMI frame countCoronary CirculationInternal medicineInternal MedicinemedicineHumansMyocardial infarctionAgedmedicine.diagnostic_testbusiness.industryFibrinolysisMicrocirculationElectrocardiography in myocardial infarctionGeneral MedicineThrombolysisMiddle AgedAtherosclerosismedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareCoronary arteriesmedicine.anatomical_structureEchocardiographyHypertensionExercise TestCardiologyFemaleRadiopharmaceuticalsmedicine.symptombusinessTIMI
researchProduct

Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? …

2016

IF 4.638; International audience; Background: Few clinical trials have focused on populations with a history of distant myocardial infarction (MI). The PEGASUS trial assessed the impact of dual antiplatelet therapy in such patients, selected by enrichment criteria of high cardiovascular risk. Whether the PEGASUS population reflects the risk of a broader post-MI population is questionable. We analyzed whether 4-year mortality of a routine-practice population would differ according to the inclusion and exclusion criteria used in PEGASUS.Methods: FAST-MI is a nationwide French registry recruiting acute MI patients in November 2005; 2490 patients alive and without recurrent MI at one year were …

MaleTicagrelorMyocardial Infarction030204 cardiovascular system & hematologyCoronary artery diseaselaw.inventionCoronary artery disease0302 clinical medicineRandomized controlled trialRisk FactorslawSecondary PreventionRegistriesSurvivors030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as TopicAged 80 and overeducation.field_of_studyReperfusion therapyEvidence-Based PharmacotherapyMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemST-elevation myocardial infarctionPopulation SurveillanceInclusion and exclusion criteriaFemaleFranceAtherothrombotic EventsCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyPopulationAcute St-ElevationAcute myocardial infarctionVorapaxar03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansMortalityeducationSelection (genetic algorithm)AgedAspirinbusiness.industryPatient SelectionAntiplatelet therapymedicine.diseaseComorbidityClinical trialAdherencePhysical therapyTherapybusinessFollow-Up Studies
researchProduct

Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?

2016

MaleTicagrelormedicine.medical_specialtyAdenosinePrasugrel030204 cardiovascular system & hematologySTEMI03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineP2Y12Internal medicinemedicineHumans030212 general & internal medicineAgedbusiness.industryMiddle AgedMagnetic Resonance ImagingMicrovesselsPurinergic P2Y Receptor AntagonistsCardiologyST Elevation Myocardial InfarctionMVOFemaleCardiology and Cardiovascular MedicinebusinessPrasugrelPrasugrel HydrochlorideTicagrelorPlatelet Aggregation InhibitorsMRImedicine.drugInternational Journal of Cardiology
researchProduct

Is high-sensitivity troponin, alone or in combination with copeptin, sensitive enough for ruling out NSTEMI in very early presenters at admission? A …

2019

Objectives: Copeptin and high-sensitivity cardiac troponin (HS-cTn) assays improve the early detection of non-ST-segment elevation myocardial infarction (NSTEMI). Their sensitivities may, however, be reduced in very early presenters.Setting: We performed a post hoc analysis of three prospective studies that included patients who presented to the emergency department for chest pain onset (CPO) of less than 6 hours.Participants: 449 patients were included, in whom 12% had NSTEMI. CPO occurred 4 hours in 146 patients. The prevalence of NSTEMI was similar in all groups (9%, 13% and 12%, respectively, p=0.281).Measures: Diagnostic performances of HS-cTn and copeptin at presentation were examined…

MaleTime Factors030204 cardiovascular system & hematologyChest pain0302 clinical medicinehigh sensitive cardiac troponinTroponin IMedicine1506Prospective Studies030212 general & internal medicineMyocardial infarctionNon-ST Elevated Myocardial InfarctionProspective cohort studynon st-elevation acute myocardial infarction[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTroponin TRGlycopeptidesGeneral MedicineMiddle Aged3. Good healthchest pain onsetEmergency MedicineCardiologyMedicineFemalevery early presentersmedicine.symptomEmergency Service HospitalAdultmedicine.medical_specialtychest pain03 medical and health sciencesCopeptinPredictive Value of TestsInternal medicinePost-hoc analysisHumansAgedbusiness.industryResearchTroponin IcopeptinEmergency departmentmedicine.disease1691businessBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct